Alvityl® Vitalité 50+
Food supplement declared in France, declaration No 2022-2-1086, decision dated 22 February 2022
Alvityl® Vitalité 50+ is a food supplement declared in France. Status: déclaré en France, commercialisation possible : l'administration ne s'est pas opposée à la déclaration (ce n'est ni une autorisation ni une évaluation de sécurité). None of the rules we check flags an issue with its declared composition; vitamin and mineral doses are not published by Compl'Alim and are therefore not checked.
- Brand
- not provided
- Food business operator placing the product on the market
- LABORATOIRES URGO HEALTHCARE
- Status
- Déclaré en France, commercialisation possible : l'administration ne s'est pas opposée à la déclaration (ce n'est ni une autorisation ni une évaluation de sécurité)
- Form
- Comprimé
- Daily dose
- 1 comprimé effervescent par jour
- Directions for use
- 1 comprimé effervescent par jour à dissoudre dans un grand verre d'eau (250 ml)
- Intended populations
- Personnes de plus de 60 ans, Homme, Femme
- Not recommended for (according to the manufacturer)
- Femmes allaitantes, Femmes enceintes, Hypertension
- Objectives stated by the manufacturer (these are not authorised claims)
- Os, Œil / Vision, Immunité
- Flavourings
- Tropical
Declaration 231604, procedure Article 15. Compl'Alim, food supplement declarations (France), retrieved 23 October 2026.
Regulatory points
None of the rules we check applies to the declared ingredients.
Declared composition
Plants
| Plant | Part | Preparation | Per day |
|---|---|---|---|
| Eleutherococcus senticosus (Rupr. et Maxim.) Maxim | Racine | Extrait sec hydroalcoolique | 180 mg |
| Vaccinium myrtillus L. | Fruit | Extrait sec aqueux | 10 mg |
Other active ingredients
| Name | Per day |
|---|---|
| Lutéine | not declared |
Vitamins and minerals
Compl'Alim does not publish vitamin and mineral doses. The references below help you read the product label: EFSAEuropean Food Safety Authority. safety limit for adults and maximum dose set in France per product (Order of 9 May 2006, not revised since November 2006).
| Declared form | Nutrient | EFSA limit, adults | Maximum dose in France |
|---|---|---|---|
| D-pantothénate de calcium | Acide pantothénique (vitamine B5) | pas de limite (données insuffisantes) | dose annulée par le Conseil d'État en 2011 |
| D-biotine | Biotine (vitamine B8) | pas de limite (données insuffisantes) | dose annulée par le Conseil d'État en 2011 |
| Sels calciques de l'acide orthophosphorique | Calcium | 2,500 mg | 800 mg |
| Sulfate de cuivre | Cuivre | 5,000 µg | 2,000 µg |
| Sel de sodium de l'édétate de fer (III) | Fer | 40 mg (niveau de sécurité) | 14 mg |
| L-méthylfolate de calcium | Folates (vitamine B9) | 1,000 µg | 200 µg |
| Carbonate de magnésium | Magnésium | 250 mg | 300 mg |
| Sulfate de manganèse | Manganèse | 8 mg (niveau de sécurité) | 3.5 mg |
| Molybdate de sodium | Molybdène | 600 µg | 150 µg |
| Nicotinamide | Nicotinamide (vitamine B3) | 900 mg | 54 mg |
| Sélénite de sodium | Sélénium | 255 µg | 50 µg |
| Acétate de rétinyle | Vitamine A | 3,000 µg d'équivalent rétinol | 800 µg |
| Chlorhydrate de thiamine | Vitamine B1 (thiamine) | pas de limite (données insuffisantes) | dose annulée par le Conseil d'État en 2011 |
| Cyanocobalamine | Vitamine B12 | pas d'effet indésirable défini | dose annulée par le Conseil d'État en 2011 |
| Riboflavine 5'-phosphate | Vitamine B2 (riboflavine) | pas de limite (données insuffisantes) | dose annulée par le Conseil d'État en 2011 |
| Chlorhydrate de pyridoxine | Vitamine B6 | 12 mg | 2 mg |
| L-ascorbate de sodium | Vitamine C | pas de limite (données insuffisantes) | 180 mg |
| Acide L-ascorbique | Vitamine C | pas de limite (données insuffisantes) | 180 mg |
| Cholécalciférol | Vitamine D | 100 µg (4,000 UI) | 5 µg (200 UI) |
| Acétate de DL-alpha-tocophéryle | Vitamine E | 300 mg | 30 mg |
| Oxyde de zinc | Zinc | 25 mg | 15 mg |
Additives
E420, E950, E955, E330, E1521, E500
List from the declaration, administrative decision dated (Compl'Alim, food supplement declarations (France)).
Label warnings
Une consommation excessive peut avoir des effets laxatifs. Contre-indiqué dans le cas d'hypertension. L'usage prolongé de plus de 3 mois est déconseillé. Ne doit pas être utilisé par les femmes enceintes ou allaitantes.
This information reproduces the manufacturer's declaration to the administration (DGAL). It does not say whether the product is effective and does not replace advice from a doctor or pharmacist, particularly during pregnancy or when taking medication.
Official warnings (Health Canada)
Health Canada publishes warnings on these ingredients:
- Eleutherococcus senticosus (Rupr. et Maxim.) Maxim
Read the warning, when it applies and the studies cited
ELEUTHERO - ELEUTHEROCOCCUS SENTICOSUS
Route of administration: Oral (ESCOP 2003; Bradley 1992)
Cautions and warnings
Ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms persist or worsen.
Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are pregnant or breastfeeding (Barnes et al. 2007; ESCOP 2003).
2 studies cited in the text have no matching reference in the monograph (see the anomalies listed on the sources page).
Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you have an acute infection (Brinker 2010; Mills and Bone 2000).
2 studies cited in the text have no matching reference in the monograph (see the anomalies listed on the sources page).
Contraindications
Do not use if you have high blood pressure (Gardner and McGuffin 2013; Brinker 2010; Barnes et al. 2007; Blumenthal et al. 2000; Mills and Bone 2000).
5 studies cited in the text have no matching reference in the monograph (see the anomalies listed on the sources page).
- Vaccinium myrtillus L.
Read the warning, when it applies and the studies cited
BILBERRY - VACCINIUM MYRTILLUS - Buccal
Route of administration: Buccal (Blumenthal et al. 2000)
Cautions and warnings
Ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms persist or worsen.
Health Canada monograph dated 30 January 2026
BILBERRY - VACCINIUM MYRTILLUS - Oral
Route of administration: Oral (Blumenthal et al. 2000)
Cautions and warnings
Condition of application: Relief of diarrhea.
Ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms persist or worsen.
Condition of application: Slowing the progression of disorders of the eye and to relieve symptoms related to non-complicated CVI.
Ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms worsen.
They concern the ingredient, not this product or its dose. They do not replace medical advice.
Is something on this product wrong or out of date, whether you are a reader or the brand? Write to contact@compoatlas.com: every correction is published in the corrections log.